You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Contrast agents for high-sensitivity ultrasound molecular imaging of tumor angiog
SBC: TARGESON, INC. Topic: NCIDESCRIPTION (provided by applicant): Molecular imaging techniques have strong potential in the setting of preclinical research, primarily for drug discovery and basic science in the field of cancer research. In particular, high-frequency ultrasound is a powerful imaging modality for phenotyping and monitoring the response to experimental therapy. Relative to other molecular imaging techniques, ult ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Developing a plectin-1 targeted imaging agent for the detection of pancreatic can
SBC: iTi Health Topic: NCIDESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standarddiagnostic course includes CT or MRI scans which do not have optimal sensitivity and specificity for accurately diagnosing and determining resec ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Hemodynamic Co-Culture Liver Model for Drug Discovery and Assessment
SBC: HemoShear Therapeutics, LLC Topic: NIDDKDESCRIPTION (provided by applicant): Drug developers desperately need better tools in the laboratory to improve the 90% failure rate of drugs in clinical trials. Liver toxicity is still the leading cause of drug failure, despite extensive preclinical testing in surrogate animal species. HemoShear develops human surrogate technologies for target ID and validation and screening of compounds for safe ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Enhanced endophyte:poplar system for remediation of organic contaminants
SBC: Edenspace Systems Corporation Topic: NIEHSDESCRIPTION (provided by applicant): Trichloroethylene (TCE), one of the most common groundwater pollutants, is a known hepatotoxin and carcinogen. It has been widely used by industry and the military as a degreaser for metal parts: according to the Agencyfor Toxic Substances and Disease Registry, more than eight hundred Superfund sites in the United States are contaminated with TCE. Poplar, which ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Multitargeted Therapy for Age-related Macular Degeneration
SBC: Charlesson, LLC Topic: NEIDESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a sight-threatening disease which represents the leading cause of blindness and visual impairment in elderly individuals in developed countries. Recently, laser and photodynamic therapies with limited clinical benefit have been partially replaced by anti-vascular endothelial growth factor (VEGF) therapies. Clinical ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic
SBC: Charlesson, LLC Topic: NEIDESCRIPTION (provided by applicant): This Small Business Innovation project aims to develop an innovative eye drop formulation for the treatment of glaucoma and ocular hypertension. Charlesson has acquired from Danube Pharmaceuticals MSH-1001, a new smallmolecule compound (previously known as DNB-001 or KR- 31378). MSH-1001 is has both ocular hypotensive and neuroprotectant properties. It is an AT ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Continuous Oxygen Monitor for Patients on Long-Term Oxygen Therapy (COMPLY)
SBC: BARRON ASSOCIATES, INC. Topic: NHLBIDESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is responsible for more than 500,000 hospitalizations and over 100,000 deaths in the United States annually. COPD is currently the fourth leading cause of death; it is projected to become the third leading cause of death in the U.S. by 2020 and worldwide by 2030. Long-term oxygen therapy (LTOT), which is administered ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
NEURON2GPU: Transformative Neural Simulation Using Desktop GPU Technology
SBC: INFORMED SIMPLIFICATIONS, LLC Topic: NIMHDESCRIPTION (provided by applicant): Researchers are now able to perform computational physiology and pharmacology experiments on realistic model neurons with accurate geometries and full complements of membrane biophysics and biochemistry; however, the practical utility of such simulations are restricted because of the limitations of current commodity computer hardware. We will provide real time, ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Web-Based Program to Improve Antidepressant Medication Adherence
SBC: ISA ASSOCIATES INC Topic: NIMHDESCRIPTION (provided by applicant): Mood disorders, including major depressive disorder, dysthymia, and bipolar disorder, affect nearly 21 million Americans or 9.5% of the U.S. population age 18 years of age and older. Among mental health problems, majordepressive disorder is the leading cause of disability in the U.S. for people ages 15-44, affecting nearly 15 million adults each year. While res ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
An Intelligent Capsule Endoscopy Video Analysis Software Platform
SBC: Xyken, LLC Topic: NIDDKDESCRIPTION (provided by applicant): Gastrointestinal (GI) malignancies are the most common cause of cancer in the world. Of the 10.8 million people in the world each year who develop cancer, approximately 3.3 million have GI malignancies. Until recently,the only sections of the GI tract that could be imaged were the esophagus, stomach and colon through traditional endoscopy. Initial segments of t ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health